KEGG   DRUG: Amivantamab and vorhyaluronidase alfa (genetical recombination)
Entry
D13229            Mixture   Drug                                   
Name
Amivantamab (genetical recombination) and vorhyaluronidase alfa (genetical recombination);
Rybrofaz (TN)
Component
Amivantamab [DR:D11894], Hyaluronidase (human recombinant) [DR:D06604]
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03162  EGFR inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FX18
Efficacy
Antineoplastic
Target
EGFR* [HSA_VAR:1956v2] [HSA:1956] [KO:K04361]
MET [HSA:4233] [KO:K05099]
  Pathway
hsa04010  MAPK signaling pathway
hsa04014  Ras signaling pathway
hsa04015  Rap1 signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04510  Focal adhesion
hsa04520  Adherens junction
hsa05200  Pathways in cancer
hsa05223  Non-small cell lung cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX18 Amivantamab
      D13229  Amivantamab (genetical recombination) and vorhyaluronidase alfa (genetical recombination)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D13229  Amivantamab (genetical recombination) and vorhyaluronidase alfa (genetical recombination)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03162  EGFR inhibitor
     D13229  Amivantamab and vorhyaluronidase alfa (genetical recombination)
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    EGFR* [HSA_VAR:1956v2]
     D13229  Amivantamab (genetical recombination) and vorhyaluronidase alfa (genetical recombination)
   MET family
    MET
     D13229  Amivantamab (genetical recombination) and vorhyaluronidase alfa (genetical recombination)
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D13229
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D13229
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system